The three small-cap biotech stocks highlighted in today’s article have seen their stocks soar this year – from 380% up to 2600% – on their respective plans to develop COVID-19 vaccines. And while none of these stocks are well-suited for the average investor, more aggressive investors may want to keep them on their radars, as the author notes that “Each of these stocks could become even bigger winners than they’ve already been if their COVID-19 programs are successful.” For more, CLICK HERE.